Immuron Ltd — Regulatory Filings 2007

Aug 15, 2007

==> picture [67 x 76] intentionally omitted <==

Company Announcement

Anadis forecasts 85% jump in functional food revenue

Thursday 16 August 2007

Melbourne, Australia - Anadis Limited (ASX:ANX), a research-driven biotechnology company focused on polyclonal antibodies to address human disease, today announced it is expecting revenue through its functional food division to increase to at least $8 million for the 2007-2008 financial year, representing an increase of more than 85% on the previous year.

In addition to developing solutions against diseases, including influenza, cancer- related mucositis and anthrax, Anadis specializes in using its know-how and experience in discovery, formulation and manufacturing to assist partners bring to market healthpromoting foods and food supplements.

“Our manufacturing and blending facility is GMP (Good Manufacturing Practice) approved and is fully compliant at both state and international HACCP levels,” said Anadis General Manager Fred Mears. “The significant increase we are experiencing in revenue in this segment – including the growing functional foods area – is a reflection of our emphasis on unique formulations and high quality.”

Anadis Chairman Roman Zwolenski said: “The expected uplift in contracted manufacturing revenue is a very pleasing development for Anadis and an important contributor to the company’s business turnaround program.”

For further information contact:

Dr Zeil Rosenberg (US) - CEO

Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Mr Roman Zwolenski - Chairman

Email: roman.z@anadis.com.au Tel: +61 3 9358 6388

Arie Nudel – Investor Relations

Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

==> picture [49 x 55] intentionally omitted <==

About Anadis Limited

Anadis Limited (ASX: ANX) is a research-driven biotechnology company focused on antibodybased therapeutic and preventive products. Anadis’ proprietary rapid manufacturing technology has enabled it to develop a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases.

The all-natural platform, and its regulatory classification as food rather than as a biological or drug, allows for a significantly shorter time-frame from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability compared to typical antibody-based solutions.

Anadis is addressing existing market opportunities sized in excess of A$35 billion (US$30 billion).

Via the leveraging of a technology platform that has been carefully developed over a decade, the company expects to become the leading provider of proprietary polyclonal antibody-based solutions worldwide.

Pipeline

Target markets include both products and technologies the company plans to manufacture itself as well as out-license. The pipeline expected to reach the market over the coming few years includes:

• Influenza Oral solution providing immediate-acting prevention and possible treatment of pandemic and seasonal influenza. The Anadis antibody platform allows for rapid modifications of the antibody profile in order to address new, emerging strains (e.g. avian influenza). Clinical studies are expected to begin in 2008.

• Bio-Defense: Diagnosis, containment and environmental decontamination A health and emergency response worker protection system against anthrax, plague and other bio-warfare agents with expansion potential to more routine bio-hazards including infectious agents, toxins and chemicals. The project received an award from The Australian Defense Department Science and Technology Office.

• Nosocomial infections Oral solutions for the prevention and treatment for top priority hospital and community acquired nosocomial infections. Anadis plans to conduct clinical studies for Clostridium difficile (C. difficile) in 2007-08.

• Enteric disease conditions including:

• Travellers’ Diarrhoea ( enterotoxigenic E. coli ). Anadis’ product, Travelan, is already being sold in Australia and has a global market. Initial shipments are being made to South Africa and Canada.

• Inflammatory bowel disease and irritable bowel syndrome (IBD and IBS). A clinical study for use as an adjunct therapy in patients with Inflammatory Bowel Disease (IBD) started in late 2006 and is being expanded to a multi-centre study.

• Chemotherapy-associated mucositis and Radiotherapy-induced enteritis, diarrhoea and other conditions that involve damage to the GI system. A clinical study begins in 2007.

• BioShielding Proprietary drug-delivery technology to protect orally administered and fragile drugs, antibodies and vaccines from degradation in the digestion system. The technology platform also permits freeze-drying of proteins and vaccines onto dry food, enabling use of dairy-derived antibodies in food. Anadis is in commercialization discussions with pharmaceutical and food manufacturing partners.

• Oncology Several major cancer research groups at major academic medical centers have indicated their interest to co-develop with Anadis the use of polyclonal antibodies in conjunction with their own proprietary oncology treatment approaches. Anadis expects to initiate animal and clinical studies during 2007-08.